Drug Type Small molecule drug |
Synonyms ATG 019, ATG-019, KCP-9274 |
Target |
Mechanism NAMPT inhibitors(Nicotinamide phosphoribosyltransferase inhibitors), PAK4 inhibitors(Serine/threonine-protein kinase PAK 4 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC35H29F3N4O3 |
InChIKeyMRFOPLWJZULAQD-SWGQDTFXSA-N |
CAS Registry1643913-93-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | - | 22 Jun 2022 | |
Hodgkin's Lymphoma | Phase 1 | CN | 30 Jun 2022 | |
Hodgkin's Lymphoma | Phase 1 | CN | 30 Jun 2022 | |
Hodgkin's Lymphoma | Phase 1 | CN | 30 Jun 2022 | |
Refractory acute myeloid leukemia | Phase 1 | US | 27 Aug 2021 | |
Relapsing acute myeloid leukemia | Phase 1 | US | 27 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 01 Jun 2016 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 01 Jun 2016 | |
Non-Hodgkin Lymphoma | Phase 1 | CA | 01 Jun 2016 |
NCT02702492 (ESMO2017) Manual | Phase 1 | 14 | vlzyojfgqj(vqyccslbdl) = Not reached bbspjklkcp (oyordxsgan ) View more | Positive | 09 Sep 2017 | ||
Phase 1 | 60 | epbjcuyqnt(osgoymafrc) = Doses up to 4 mg/kg KPT-9274 were well tolerated with no grade ≥3 toxicities. At 4.5 mg/kg one dog exhibited severe vomiting, diarrhea, collapse, anemia and thrombocytopenia, establishing 4 mg/kg as MTD. No unexpected toxicities were noted with the combination when compared to those expected from DOX alone. hguxwubsju (ijkmwvhunh ) View more | Positive | 01 Jul 2017 |